Announcements Trials
Browse Landscape

Status

Completed 3Unknown 2

Sponsor Class

INDUSTRY 5

Study Type

Observational 5Interventional 2

Sponsor

Conditions

Breast Neoplasms 467Neoplasms 315Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 207Lung Neoplasms 176Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 59Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

Fentanyl 3Nasal Sprays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Breakthrough Cancer Pain × Clear all
NCT03895762 2022-05-05

OASIS

A.Menarini Asia-Pacific Holdings Pte Ltd

Completed
143 enrolled

Breakthrough Cancer Pain

NCT02899884 2019-11-22

Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain

Takeda

Completed
3,765 enrolled 10 charts

Breakthrough Cancer Pain

NCT01693328 2014-01-15

Qualipec

Archimedes Development Ltd

Unknown
300 enrolled

Breakthrough Cancer Pain

NCT01698645 2013-07-11

Qualipec

Archimedes Development Ltd

Unknown
150 enrolled

Breakthrough Cancer Pain

NCT01045603 2012-10-29

INIS

Takeda

Completed
309 enrolled

Breakthrough Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡